receiving the results stressful, even when the results were negative. Testing made them more anxious during their pregnancies than they had been during previous ones (even though one family had been in a Middle Eastern war zone during previous pregnancies).

Women need to be well informed before they consent to a potentially traumatic testing procedure.³ The importance of counselling, however, resides in what the patient grasps, not in what the doctor thinks that he or she has communicated. In one large study 72% of counselled women knew that maternal blood is taken for the test but 33% were unaware that further tests are offered if the result is positive, 62% did not know that the test was for Down's syndrome, and 68% were unaware that most women with positive results have normal babies.⁴ Can consent be truly informed in these circumstances?

The screening process is confusing and stressful. Whether any putative benefit outweighs the extra distress for 700 000 women each year is open to question.¹ Shouldn't our cardinal rule be first do no harm?

ALEX BUNN GEORGE IOANNOU
KAREN FORREST RUSTAM REA
Clinical medical students

Oxford University Medical School,
John Radcliffe Hospital,
Oxford OX3 9DU

- 1 Steer P. Recent advances in obstetrics. *BMJ* 1995;311:1209-12. (4 November.)
- 2 Recent advances in obstetrics [letters]. *BMJ* 1995;312:379-80. (10 February.)
- 3 Royal College of Obstetricians and Gynaecologists. *Report of the RCOG working party on biochemical markers and the detection of Down's syndrome*. London: RCOG Press, 1993.
- 4 Smith D, Shaw R, Marteau T. Informed consent to undergo serum screening for Down's syndrome: the gap between policy and practice. *BMJ* 1994;309:776.

Author's reply

EDITOR,—The letter from Anne Kennard and colleagues published in a previous issue,¹ commenting on my review of serum screening for Down's syndrome,² shows perfectly some of the traps into which the enthusiasts for this technique fall.

Firstly, they say that it is inappropriate to quote the actual detection rate but insist on using the estimated rate, which is higher. Such estimates do not take into account women who refuse the test, book too late for it, or decide not to have amniocentesis despite having a high risk. As a realist, I quoted the actual detection rates.

Secondly, they say that serum screening can be introduced for £20 a test. As a clinical director who has introduced such a service in my own trust, I would like to know how a booking scan (essential for accurate dating), blood sampling, estimation of two or three serum markers, and (at least) 20 minutes' detailed counselling could be purchased for £20. I suspect that they are considering only the cost of measuring the serum markers, which is all that our purchasers originally offered to pay for when they asked us to introduce the test. We eventually convinced them that the extra scanner plus radiographer, phlebotomist, counselling time, and organising costs all had to be funded in addition.

Alex Bunn and colleagues emphasise the importance of counselling, which takes a lot of time. Time, especially in the new style NHS, is money. I too have witnessed much confusion about the principles of screening, not only among pregnant women but also among professionals, especially general practitioners. One general practitioner wrote in a maternity record: "screen negative (1 in 900), therefore reassured that she cannot have a baby with Down's syndrome." In addition, general practitioners often have difficulty understanding why screening policies vary among providers and purchasers. In their practice women

booked with one provider may be offered both serum and nuchal translucency screening whereas women booked with another may be offered neither.

Finally, in my review I accepted the possibility that screening might have reduced the incidence of Down's syndrome at birth. This, however, remains only a hypothesis, and many other possible explanations exist. The incidence of neural tube defects has fallen dramatically in the Republic of Ireland, where antenatal screening and termination are not widely practised. I am intrigued that Kennard and colleagues are so sure that they know what is cause and effect when many of the criteria for causality (as opposed to plausible association) are not yet met.

PHILIP STEER
Professor

Academic Department of Obstetrics and Gynaecology,
Charing Cross and Westminster Medical School,
Chelsea and Westminster Hospital,
London SW10 9NH

- 1 Kennard A, Alberman E, Gill M. Recent advances in obstetrics. *BMJ* 1996;312:379. (10 February.)
- 2 Steer P. Recent advances in obstetrics. *BMJ* 1995;311:1209-12. (4 November.)

Topical acyclovir is beneficial in recurrent herpes labialis

EDITOR,—In his editorial on oral acyclovir in the management of recurrent herpes labialis Graham Worrall understates the evidence for the efficacy of topical acyclovir cream.¹ One of the principal benefits of topical 5% acyclovir cream in recurrent herpes labialis is that it terminates the condition at the prodromal stage² in addition to resulting in more rapid healing and less pain in those lesions that do develop.³ Further evidence to support the ability of the cream to prevent the development of recurrent herpes labialis past the prodromal stage comes with the use of electronic infrared thermography as a reliable, non-invasive means of confirming the prodromal stage of the condition.⁴ Preliminary results obtained with this method corroborate the earlier clinical observations: normalisation of the thermographic profile occurs when such early lesions are terminated at the prodromal stage by the cream.⁵ It therefore seems appropriate to evaluate the true benefit of topical acyclovir in the treatment of recurrent herpes labialis before addressing the value of oral acyclovir.

P-J LAMEY
Professor of oral medicine

School of Clinical Dentistry,
Queen's University of Belfast,
Royal Victoria Hospital,
Belfast BT12 6BP

- 1 Worrall G. Acyclovir in recurrent herpes labialis. *BMJ* 1996;312:6. (6 January.)
- 2 Fiddian AP, Yeo JM, Stubbings R, Dean D. Successful treatment of herpes labialis with topical acyclovir. *BMJ* 1983;286:1699-701.
- 3 Van Vloten WA, Swart RNJ, Pot F. Topical acyclovir therapy in patients with recurrent orofacial herpes simplex infections. *J Antimicrob Chemother* 1983;12:89-93.
- 4 Biagioni PA, Lamey P-J. Electronic infrared thermography as a method of assessing herpes labialis infection. *Acta Derm Venereol* 1995;75:264-8.
- 5 Lamey P-J, Biagioni PA. Thermographic resolution of the prodromal phase of herpes labialis treated with acyclovir. *Dento-Maxillo-Facial Radiology* 1995;24:201-3.

Fertility continues after age 40

EDITOR,—The numerous women who have children in their fourth and fifth decades would hardly agree that "fertility declines at 30 and is almost gone by 40"—the alarming subtitle used by Roger Gosden and Anthony Rutherford in their otherwise reasonable editorial on delayed childbearing.¹ In 1994, 8451 sets of twins were born in

Britain, and the years between ages 35 and 40 are the peak period for twin and higher order births, whether these are the outcome of assisted conception techniques or not. At age 37 the incidence of dizygotic (fraternal) twins is roughly four times that at age 20.

As for the fifth decade, in Britain around 9000 babies a year are born to mothers over 40. Many of these pregnancies are unplanned and might well not have occurred had it not been for some well intentioned but misguided doctor advising his or her patient that a woman of her age "needn't bother" with contraception any more.

The authors mention the Hutterite community in North America, but the research to which they refer is itself over 40 years old. A natural onset of infertility is by no means the only possible reason for the low number of births to women over 40, since there are, as the authors themselves suggest, a multitude of other possible explanations despite the Hutterite ban on contraception.

CAROL COOPER
General practitioner

The Surgery,
14 Cuckoo Lane,
London W7 3EY

- 1 Gosden R, Rutherford A. Delayed childbearing. *BMJ* 1995;311:1585-6. (16 December.)

Laboratories should use serum IgM tests to confirm measles

EDITOR,—We agree with Dereck R Tait and colleagues about the importance of laboratory confirmation of exanthems for surveillance purposes.¹ The salivary IgM assay has been used successfully during the recent measles and rubella vaccination campaign in selected districts² but is not yet available commercially. Serum measles IgM assays are now available, although in our experience the complement fixation test is still used widely for screening. A comparison of the methods has led us to believe that many cases of measles will be missed unless specific IgM assays are used more widely as a first line test.

During the 12 months November 1993 to October 1994 this laboratory received 608 serum samples from cases in which the clinical picture suggested possible measles. Screening with an IgM enzyme linked immunosorbent assay (ELISA; Sigma Diagnostics, St Louis, United States) yielded 50 positive results (age range 1-38 years). The positive samples were then tested by complement fixation, an alternative commercial ELISA (Biostat Diagnostics, Stockport, Cheshire), an in house immunofluorescence test, and radioimmunoassay. Forty nine of the 50 samples yielded positive results when the alternative commercial ELISA, in house immunofluorescence test, and radioimmunoassay were used, while one sample consistently gave negative results. In the complement fixation test, however, 46 of the 50 samples had titres of <160 (the accepted cut off value for performing an IgM test). A reduction in the cut off value was not realistic as 18 positive samples had titres of <20.

The complement fixation test performs best when acute and convalescent serum samples are being compared. While follow up specimens would have been requested for all the acute serum samples yielding negative results, only six were received (ages 6, 8, 13, 18, 18, 19); four showed a fourfold rise in antibody titre and two had stable titres of 20 and 80. Convalescent serum samples remain unusual, especially in children. Had we relied on the result of the complement fixation test alone (which in previous years was often obtained from a single serum sample), 80% of acute cases of measles would have been missed.

We have found both commercial and in house measles IgM tests to be reliable, and an IgM test is